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Abstract
Since the discovery of HCV, polymerase chain reaction (PCR) has significantly contributed to the understanding of
the virus life cycle and its replicative kinetics during anti-viral therapy. Parallel to the progression of dual and triple
combination treatment, real-time PCR molecular tests have constantly improved in their ability to monitor viral
load and drive personalized management schedules. The current sensitivity, accuracy and dynamic range of the
available assays fulfil the requirement of “companion diagnostics” and support the development of new directly
acting antiviral (DAA)-based regimens.
Introduction
The development of polymerase chain reaction (PCR) in
the eighties was instrumental, a few years later, to the
discovery of HCV, the first infectious disease agent iden-
tified by a reverse genetic approach. Using a library of
primers and concentrated plasma from individuals with
non-A, non-B hepatitis, M. Houghton et al. amplified
and identified the first HCV sub-genomic fragments
whose products were specifically reactive with circulating
antibodies from infected patients [1]. Proteins derived
from the initial HCV clones served as target antigens in
the first serological assay and, once validated in large
cohorts of patients with non-A, non-B hepatitis, they
were further developed into standardized immunoassays
for screening blood donations and blood derived pro-
ducts to prevent transmission.
Development of molecular methods in the
diagnosis of HCV
The first PCR-based tests were developed as confirma-
tory assays for seropositive individuals and to stage the
replicative activity of the infection. Two major technolo-
gical innovations enabled the broad uptake of these initial
PCR tests: (i) the discovery of thermo-stable enzymes
with both reverse transcription and DNA polymerase
activity (Tth polymerase); (ii) the introduction of uracyl-
N-glycosilase (Amperase®) [2,3]. The former allowed for
a single tube-single reaction PCR workflow, while the lat-
ter eliminated carry over contamination by selective inac-
tivation of amplicons from previous reactions (Figure 1).
The evidence available at that time on the clinical utility
of viral load in the area of HIV/AIDS suggested similar
indications also for the management of chronic hepatitis C
and led to the development of quantitative PCR tests
based on end-point dilution. These provided the initial
tools to investigate the association between viral load and
disease progression, as well as response to therapy.
Different response profiles were identified during inter-
feron (IFN) based therapies and a first, viral kinetics
based, predictive criterion was introduced in clinical
practise which identified, at week 12 on treatment,
patients with no probability of sustained virological
response (SVR). SVR is defined by a negative HCV RNA
test 6 months after end of treatment and indicate virus
eradication. A decrease of less than 2 logarithms at week
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12, the threshold required for the early virological
response (EVR), was found to have a very high negative
predictive value and was proposed and validated as a
“stopping rule” for treatment discontinuation.
Only after the development of the real-time, Taqman
PCR technique, it was possible to introduce truly quantita-
tive molecular test and proceed with a thorough assess-
ment of viral load kinetics and its clinical correlates. As
previously reported [4], the Taqman method is based on
dual fluorescent dye-labeled probes with a reporter and a
quencher fluorochrome at the 5´and 3´regions. In the
probe native state, the energy emitted by the reporter dye
is absorbed by the quencher, which prevents light emission.
During amplification, the probe hybridizes to its comple-
mentary target DNA and is cleaved by the exonuclease
activity of the DNA Polymerase. The two dyes are released,
quenching no longer occurs and a fluorescent signal is pro-
duced whose intensity is proportional to the amount of the
sample target DNA or RNA. Compared to the initial end-
point PCR based test, real-time assays have much broader
linear ranges and higher accuracy (Figure 2).
Using these tests, an additional, important viral load
parameter was identified at week 4 on treatment, the
rapid virological response (RVR), characterized by unde-
tectable HCV RNA, with a high positive predictive value
for SVR so as to serve as a main driver for treatment
individualization.
The recent development of DAA and the approval of
the first, boceprevir- and telaprevir-based triple-therapy
regimes, have brought new hopes for higher virus
eradication rate across different disease settings. This
calls for even more accurate and sensitive quantitative
HCV RNA tests able to monitor faster virus kinetics
and promptly detect treatment failures. Indeed, subtle
differences between a HCV RNA negative (reported as
target not detected) and a borderline HCV RNA positive
result (reported as detected <15 IU/ml), below the limit
of detection (LOD) of the most widely used real-time
PCR tests, were found to influence the RVR rate and
potentially lead to more relapses.
In this respect, we have recently introduced a new
version of the Cobas® Ampliprep™/Cobas® Taqman™
HCV 2.0 test, a fully automated real-time PCR assay,
which has a novel dual-probe design which minimizes
the impact of possible sequence mismatches (Figure 3).
Similar to the dual target approached followed in the
development of the Cobas® Ampliprep™/Cobas® Taq-
man™ HIV 2.0 test, where both the LTR and the gag
genes are amplified, the HCV 2.0 assay has an increase
genotypes inclusivity and better coverage of minor var-
iants as well as of new strains and mutants that may
emerge in the future. This new configuration also
allowed for setting a unique threshold for both the LOD
and the limit of quantification (LOQ) to improve the
interpretation of results and increase precision at the
lower end of the linear range [5,6].
Conclusions
With new viral load tests acting as “companion diagnos-
tic”, the clinical development and applications of the new
Figure 1 Amperase® mediated selected inactivation of amplicons from previous reactions. Amplicons are synthetized during PCR using dUTP
instead of dATP and made susceptible to cleavage by Amperase® which has no effect on sample, native DNA.
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Figure 2 Progressive increase in sensitivity and dynamic ranges when proceeding from end point to real-time PCR. The latter allowed for a
linear range increase of up to 4 logarithms.
Figure 3 Dual probe design of the Cobas® Ampliprep™/Cobas® Taqman™ HCV 2.0 test second version. The introduction of a second labelled
probe and an additional reverse primers increased mismatchs tolerance and assay’s accuracy.
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generation DAA can be fully supported for a more effec-
tive management of chronic hepatitis C and its long-term
complications.
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